Product Details:
| Dose/Strength | linagliptin 5mg |
| Form | Tablets |
| Composition | linagliptin 5mg |
| Packaging Type | alu-alu |
| Prescription/Non prescription | Prescription |
| Also gives | Pharmaceutical Third Party Manufacturing |
LINAGLIPTIN
It is potent, long ecting inhibitor with high selectivity for DPP-4
It shows improved glycemic control in patients with type 2 diabetes
It provides a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and sulphonylurea
METFORMIN (IR)*
Increases insulin sensitivity, improves peripheral uptake of glucose and reduces hepatic glucose output
Reduces blood glucose level without weight gain and has minimal risk of hypoglycemia
PATIENTS WITH TYPE 2 DIABETES,
ADDING LINAGLIPTIN TO METFORMIN SIGNIFICANTLY IMPROVES GLYCAEMIC CONTROL AND WELL TOLERATED.
Advantages:
Better efficacy due to better regulation of the glucose homeostasis. Better Safety due to low propensity for hypoglycaemia.
Better tolerance due to
pharmacokinetics and pharmacodynamics relevancy
of combination
